Free Trial
NASDAQ:IMUX

Immunic Q1 2025 Earnings Report

Immunic logo
$0.79 +0.02 (+2.01%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.79 +0.01 (+0.71%)
As of 06/6/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunic EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.25
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Immunic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunic Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Immunic's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Earnings Documents

Immunic Earnings Headlines

Q2 Earnings Estimate for Immunic Issued By Leerink Partnrs
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
See More Immunic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email.

About Immunic

Immunic (NASDAQ:IMUX), a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

View Immunic Profile

More Earnings Resources from MarketBeat